Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G3SH
|
|||
| Former ID |
DAP000873
|
|||
| Drug Name |
Ursodeoxycholic acid
|
|||
| Synonyms |
Actigall; Antigall; Arsacol; Delursan; Destolit; Deursil; Litursol; Lyeton; Peptarom; Solutrat; UDCA; UDCS; UrSO; Urosiol; Ursacol; Ursobilin; Ursochol; Ursodamor; Ursodeoxycholate; Ursodiol; Ursofalk; Ursolvan; Ursosan; Acide ursodesoxycholique; Acido ursodeossicolico; Acido ursodeossicolico [Italian]; Acido ursodeoxicolico; Acidum ursodeoxycholicum; Deoxyursocholic Acid; Sodium Ursodeoxycholate; Ursacholic Acid; Urso DS; Urso Forte; Ursodeoxy cholic acid; Ursodesoxycholicacid; Ursodexycholic Acid; Ursodiol [USAN]; IU5; U0030; Urso 250; Acide ursodesoxycholique [INN-French]; Acido ursodeoxicolico [INN-Spanish]; Acidum ursodeoxycholicum [INN-Latin]; Actigall (TN); Cholit-ursan; Deursil (TN); Dom-ursodiol c; ISO-URSODEOXYCHOLIC ACID; PHL-ursodiol c; PMS-ursodiol c; U-9000; Urso (TN); Urso Forte (TN); Ursodiol (USP); Ursosan (TN); Ursodeoxycholic acid (JP15/INN); Ursodeoxycholic acid, UDCA, Ursosan, Ursofalk, Urso Forte, Udiliv, Ursodiol; Cholan-24-oic acid, 3,7-dihydroxy-, (3-alpha,5-beta,7-beta)-(9CI); (3alpha,5beta,7beta)-3,7-dihydroxycholan-24-oic acid; (3alpha,5beta,7beta,8xi)-3,7-dihydroxycholan-24-oic acid; (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid; 17-beta-(1-Methyl-3-carboxypropyl)etiocholane-3-alpha,7-beta-diol; 3 alpha,7 beta-Dihydroxy-5 beta-cholan-24-oic Acid; 3,7-Dihydroxycholan-24-oic acid; 3-alpha,7-beta-Dihydroxy-5-beta-cholanoic acid; 3-alpha,7-beta-Dihydroxycholanic acid; 3-alpha,7-beta-Dioxycholanic acid; 3alpha,7beta-Dihydroxy-5beta-cholan-24-oic acid; 3alpha,7beta-Dihydroxy-5beta-cholanic acid; 5beta-Cholan-24-oic acid-3alpha,7beta-diol; 5beta-Cholanic Acid-3alpha,7beta-diol; 7-beta-Hydroxylithocholic acid; 7beta-Hydroxylithocholic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Primary biliary cirrhosis [ICD-11: DB96.1; ICD-10: K74.3; ICD-9: 571.6] | Approved | [1], [2] | |
| Therapeutic Class |
Cholagogues and Choleretics
|
|||
| Company |
Axcan Pharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H40O4
|
|||
| Canonical SMILES |
CC(CCC(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C
|
|||
| InChI |
1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20+,22+,23+,24-/m1/s1
|
|||
| InChIKey |
RUDATBOHQWOJDD-UZVSRGJWSA-N
|
|||
| CAS Number |
CAS 128-13-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10082, 822713, 3138790, 7847799, 7850921, 7888488, 7980868, 8172159, 11433256, 11466986, 11468106, 11486841, 11532904, 14718187, 14756614, 14780856, 24900651, 29204656, 34673541, 46508795, 47193720, 47217051, 47515582, 47885649, 48110725, 48185236, 48416690, 49699224, 49748670, 49902961, 50124074, 53788379, 57311214, 78337565, 87577760, 92125922, 92717068, 99431529, 102851587, 103578669, 103913836, 104169985, 104253279, 104310778, 121362367, 121363593, 124757400, 124800594, 125085062, 125164204
|
|||
| ChEBI ID |
CHEBI:9907
|
|||
| ADReCS Drug ID | BADD_D02321 | |||
| SuperDrug ATC ID |
A05AA02
|
|||
| SuperDrug CAS ID |
cas=000128132
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
| Studied Microbe: Gut microbiota unspecific | [3] | |||
| Experimental Method | High-throughput screening | |||
| Description | Ursodiol can be metabolized by gut microbiota. | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Biliverdin reductase A (BLVRA) | Target Info | Activator | [4], [5] |
| Solute carrier family 23 member 2 (SLC23A2) | Target Info | Activator | [4], [5] | |
| BioCyc | Heme degradation | |||
| KEGG Pathway | Porphyrin and chlorophyll metabolism | |||
| Pathwhiz Pathway | Porphyrin Metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7104). | |||
| REF 2 | Drug information of Ursodeoxycholic acid, 2008. eduDrugs. | |||
| REF 3 | Personalized Mapping of Drug Metabolism by the Human Gut Microbiome. Cell. 2020 Jun 25;181(7):1661-1679.e22. | |||
| REF 4 | Role of vitamin C transporters and biliverdin reductase in the dual pro-oxidant and anti-oxidant effect of biliary compounds on the placental-fetal... Toxicol Appl Pharmacol. 2008 Oct 15;232(2):327-36. | |||
| REF 5 | Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. Hepatology. 2007 Oct;46(4):1131-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.